Amyloidosis and Bleeding: Pathophysiology, Diagnosis, and Therapy

American Journal of Kidney Diseases

Volumn 47, Issue 6, 2006, Pages 947-955

  Sucker, Christoph ^a   Hetzel, Gerd Ruediger ^a   Grabensee, Bernd ^a   Stockschlaeder, Marcus ^a   Scharf, Ruediger E ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

amyloid deposition; Amyloidosis; bleeding; coagulation factor deficiency; hyperfibrinolysis; platelet dysfunction

Indexed keywords

AMYLOID; ANTIFIBRINOLYTIC AGENT; ANTIPLASMIN; DESMOPRESSIN; DEXAMETHASONE; MELPHALAN; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THALIDOMIDE; TRANEXAMIC ACID;

AMYLOIDOSIS; BIOPSY; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD VESSEL; FIBRIN POLYMERIZATION; FIBRINOLYSIS; GASTROINTESTINAL HEMORRHAGE; HUMAN; REVIEW; RISK FACTOR; THROMBOCYTE DYSFUNCTION; VASCULAR AMYLOIDOSIS; VASOCONSTRICTION;

AMYLOID; AMYLOIDOSIS; ANGIOGENESIS INHIBITORS; BLOOD COAGULATION; BLOOD PLATELET DISORDERS; BLOOD VESSELS; COAGULANTS; COAGULATION PROTEIN DISORDERS; DRUG THERAPY; FIBRINOLYSIS; HEMORRHAGE; HUMANS; RISK FACTORS; STEM CELL TRANSPLANTATION;

EID: 33646773262     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.03.036     Document Type: Review

References (95)

1. Merlini G., and Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 349 (2003) 583-596
2. Westermark P., Benson M.D., Buxbaum J.N., et al., Nomenclature Committee of the International Society of Amyloidosis. Amyloid: Toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 12 (2005) 1-4
3. Holmgren G., Ericzon B.G., Groth C.G., et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341 (1993) 1113-1116
4. Snanoudj R., Durrbach A., Gauthier E., et al. Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantation. Nephrol Dial Transplant 9 (2004) 1779-1785
5. Zeldenrust S., Gertz M., Uemichi T., et al. Orthotopic liver transplantation for hereditary fibrinogen amyloidosis. Transplantation 75 (2003) 560-561
6. Dispenzieri A., Lacy M.Q., Kyle R.A., et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 19 (2001) 3350-3356
7. Drewe E., Huggins M.L., Morgan A.G., Cassidy M.J., and Powell R.J. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 43 (2004) 1405-1408
8. Gottenberg J.E., Merle-Vincent F., Bentaberry F., et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides. A followup report of tolerability and efficacy. Arthritis Rheum 48 (2003) 2019-2024
9. Skinner M., Sanchorawala V., Seldin D.C., et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis. An 8-year-study. Ann Intern Med 140 (2004) 85-93
10. Lundmark K., Westermark G.T., Nystrom S., Murphy C.L., Solomon A., and Westermark P. Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci U S A 99 (2002) 6979-6984
11. Lachmann H.J., Gallimore R., Gillmore J.D., et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122 (2003) 78-84
12. Hawkins P.N., Aprile C., Capri G., et al. Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. Eur J Nucl Med 25 (1998) 701-708
13. Gamba G., Montani N., Anesi E., et al. Clotting alterations in primary systemic amyloidosis. Haematologica 85 (2000) 289-292
14. Kyle R.A., and Gertz M.A. Primary systemic amyloidosis. Clinical and laboratory features in 474 cases. Semin Hematol 32 (1995) 45-59
15. Mumford A.D., O'Donnell J., and Gillmore J.D. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol 110 (2000) 454-460
16. Revesz T., Ghiso J., Lashley T., et al. Cerebral amyloid angiopathies. A pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 62 (2003) 885-898
17. Okuda Y., Takasugi K., Oyama T., Onuma M., and Oyama H. Amyloidosis in rheumatoid arthritis-Clinical study of 124 histologically proven cases. Ryumachi 34 (1994) 939-946
18. Vinters H.V., and Gilbert J.J. Cerebral amyloid angiopathy. Incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke 14 (1983) 924-928
19. Rosand J., Muzikansky A., Kumar A., et al. Spatial clustering of hemorrhages in probable cerebral amyloid angiopathy. Ann Neurol 58 (2005) 459-462
20. Maeshima E., Yamada Y., and Yukawa S. Massive gastrointestinal hemorrhage in a case of amyloidosis secondary to rheumatoid arthritis. Scand J Rheumatol 28 (1999) 262-264
21. Usui M., Matsuda S., Suzuki H., Hirata K., Ogura Y., and Shiraishi T. Gastric amyloidosis with massive bleeding requiring emergency surgery. J Gastroenterol 35 (2000) 924-928
22. Pamuk G.E., Pamuk O.N., Altiparmak M.R., Tanverdi M., Uygun N., and Yurdakul S. Secondary amyloidosis in progressive systemic sclerosis. Clin Rheumatol 20 (2001) 285-287
23. Youssef N., Carbonell N., Bonte H., Serfaty L., Poupon R., and Flejou J.F. Fatal Dieulafoy's type ulcer in a case of gastric AL-amyloidosis. Ann Pathol 24 (2004) 256-258
24. Iwahashi N., Tame E., Nagasaka T., Furuta M., Nagashima H., and Nimura Y. Massive hemorrhage and pseudo-obstruction of the small intestine caused by primary AL amyloidosis associated with gastric cancer. Report of a case. Surg Today 34 (2004) 871-874
25. 2-Microglobulin-derived amyloidosis. An update. Kidney Int Suppl 78 (2001) S164-S171
26. 2-microglobulin-derived amyloidosis in patients who undergo long-term hemodialysis. Report of seven cases and review of the literature. Arch Pathol Lab Med 118 (1994) 718-721
27. 2-microglobulin amyloidosis correlates with time on dialysis. Am J Surg Pathol 22 (1998) 729-735
28. 2-microglobulin amyloidosis. A case report and review of the literature. Arthritis Rheum 53 (2005) 142-145
29. Eiro M., Katoh T., and Watanabe T. Risk factors for bleeding complications in percutaneous renal biopsy. Clin Exp Nephrol 9 (2005) 40-45
30. Bieber T., Ruzicka T., Linke R.P., von Kries R., Goerz G., and Braun-Falco O. Hemorrhagic bullous amyloidosis. A histologic, immunocytochemical, and ultrastructural study of two patients. Arch Dermatol 124 (1988) 1683-1686
31. Stammler F. Haemorrhagic diathesis as an early symptom of systemic amyloidosis. Dtsch Med Wochenschr 131 (2006) 17-21
32. Kiuru-Enari S., Keski-Oja J., and Haltia M. Cutis laxa in hereditary gelsolin amyloidosis. Br J Dermatol 152 (2005) 250-257
33. Boorjian S., Choi B., Loo M., Kim P., and Sandhu J. A rare case of painless gross hematuria. Primary localized AA-type amyloidosis of the urinary bladder. Urology 59 (2002) 137iii-137iv
34. Caglar K., Kibar Y., Tahmaz L., and Safali M. Laser therapy in patient with intractable haemorrhage due to the bladder involvement of systemic amyloidosis. Nephrol Dial Transplant 16 (2001) 174
35. Emori Y., Sakugawa M., Niiya K., et al. Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis. Blood Coagul Fibrinolysis 13 (2002) 555-559
36. Khan A.Z., Escofet X., Roberts K.M., and Salman A.R. Spontaneous splenic rupture-A rare complication of amyloidosis. Swiss Surg 9 (2003) 92-94
37. Enjeti A.K., Walsh M., and Seldon M. Spontaneous major bleeding in acquired factor X deficiency secondary to AL-amyloidosis. Haemophilia 11 (2005) 535-538
38. Rapoport M., Yona R., Kaufman S., Segal M., and Kornberg A. Unusual bleeding manifestations of amyloidosis in patients with multiple myeloma. Clin Lab Haematol 16 (1994) 349-353
39. Furuya S., Masumori N., Furuya R., Tsukamoto T., Isomura H., and Tamakawa M. Characterization of localized seminal vesicle amyloidosis causing hemospermia. An analysis using immunohistochemistry and magnetic resonance imaging. J Urol 173 (2005) 1273-1277
40. Taylor E., Gilks B., and Lanvin D. Amyloidosis of the uterine cervix presenting as postmenopausal bleeding. Obstet Gynecol 98 (2001) 966-968
41. Choufani E.B., Sanchorawala V., Ernst T., et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis. Incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 97 (2001) 1885-1887
42. Furie B., Voo L., McAdam K.P., and Furie B.C. Mechanism of factor X deficiency in systemic amyloidosis. N Engl J Med 304 (1981) 827-830
43. Girmann G., Wilker D., Stadie H., and Scheurlen P.G. Acquired isolated factor X deficiency associated with systemic amyloidosis. Case report and review of the literature. Klin Wochenschr 58 (1980) 859-862
44. Greipp P.R., Kyle R.A., and Bowie E.J. Factor-X deficiency in amyloidosis. A critical review. Am J Hematol 11 (1981) 443-450
45. McPherson R.A., Onstad J.W., Ugoretz R.J., and Wolf P.L. Coagulopathy in amyloidosis. Combined deficiency of factors IX and X. Am J Hematol 3 (1977) 225-235
46. Gatel A., Cacoub P., and Piette J.C. AL amyloidosis combined with acquired factor V deficiency. Ann Intern Med 128 (1998) 604-605 letter
47. Maroy N. Acquired deficit in factor X associated with amyloidosis. One case. Nouv Presse Med 7 (1978) 3441-3442
48. Duncan E.M., Cole J., Clarkson A.R., and Lloyd J.V. Poor recovery and short survival of infused factor X in a case of acquired factor X deficiency and amyloidosis. Thromb Haemost 82 (1999) 1375-1376
49. Boggio L., and Green D. Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency. Br J Haematol 112 (2001) 1074-1075
50. Takabe K., Holman P.R., Herbst K.D., Glass C.A., and Bouvet M. Successful perioperative management of factor X deficiency associated with primary amyloidosis. J Gastrointest Surg 8 (2004) 358-362
51. Gastineau D.A., Gertz M.A., Daniels T.M., Kyle R.A., and Bowie E.J. Inhibitor of the thrombin time in systemic amyloidosis. A common coagulation abnormality. Blood 77 (1991) 2637-2640
52. Aoki N. Hemostasis associated with abnormalities of fibrinolysis. Blood Rev 3 (1989) 11-17
53. Elkayam O., Hawkins P.N., Lachmann H., Yaron M., and Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 46 (2002) 2571-2573
54. Millard L.G., and Rowell N.R. Primary amyloidosis and myelomatosis associated with excessive fibrinolytic activity. Br J Dermatol 94 (1976) 569-571
55. Podorolskaia L.V., Andreenko G.V., Poliantseva L.R., and Bumblite I.D. Fibrinolytic activity of the urine during chronic glomerulonephritis and amyloidosis. Vopr Med Khim 45 (1999) 158-164
56. Haan J., Kluft C., Leebeek F.W., de Bart A.C., Buruma O.J., and Roos R.A. Hereditary cerebral hemorrhage with amyloidosis-Dutch type. A study of fibrinolysis. Thromb Haemost 67 (1992) 16-18
57. Boudes P., Horellou M.H., Bletry O., et al. AL amyloidosis and primary fibrinolysis. Study of the mechanism of fibrinolysis. Ann Med Interne (Paris) 140 (1989) 41-44
58. Liebman H.A., Carfagno M.K., Weitz I.C., et al. Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase. Am J Clin Pathol 98 (1992) 534-541
59. Sane D.C., Pizzo S.V., and Greenberg C.S. Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis. Case report and literature review. Am J Hematol 31 (1989) 53-57
60. Takahashi H., Koike T., Yoshida N., et al. Excessive fibrinolysis in suspected amyloidosis. Demonstration of plasmin-alpha 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma. Am J Hematol 23 (1986) 153-166
61. Chang J.C., and Kane K.K. Pathologic hyperfibrinolysis associated with amyloidosis. Clinical response to epsilon amino caproic acid. Am J Clin Pathol 81 (1984) 382-387
62. Meyer K., and Williams E.C. Fibrinolysis and acquired alpha-2 plasmin inhibitor deficiency in amyloidosis. Am J Med 79 (1985) 394-396
63. Charyev B.M., Kozlovskaia N.L., Kozlovskaia L.V., and Mishchenko A.L. Characteristics of the aggregative function of thrombocytes in amyloidosis. Ter Arkh 60 (1988) 85-88
64. Demiroglu H., Barista I., Gursoy M., Oymak O., and Dundar S. The effect of desmopressin on platelet aggregation defect in systemic amyloidosis. A preliminary report. Eur J Haematol 56 (1996) 283-286
65. Kiuru S., Javela K., Somer H., and Kekomaki R. Altered platelet shape change in hereditary gelsolin Asp187Asn-related amyloidosis. Thromb Haemost 83 (2000) 491-495
66. Dave S.P., Greenstein A.J., Sachar D.B., Harpaz N., and Aledort L. Bleeding diathesis in amyloidosis with renal insufficiency associated with Crohn's disease. Response to desmopressin. Am J Gastroenterol 97 (2002) 187-189
67. Hoshino Y., Hatake K., and Muroi K. Bleeding tendency caused by the deposit of amyloid substance in the peri-vascular region. Intern Med 32 (1993) 879-881
68. Alwitry A., Brackenbury E.T., Beggs F.D., and Soomro I. Vascular amyloidosis causing spontaneous mediastinal haemorrhage with haemothorax. Eur J Cardiothorac Surg 20 (2001) 871-873
69. Hamzavi I., and Lui H. Excess tissue friability during CO2 laser vaporization of nodular amyloidosis. Dermatol Surg 25 (1999) 726-728
70. Nurmi M.J., Ekfors T.O., and Puntala P.V. Secondary amyloidosis of the bladder. A cause of massive hematuria. J Urol 138 (1987) 44-45
71. Taylor E., Gilks B., and Lanvin D. Amyloidosis of the uterine cervix presenting as postmenopausal bleeding. Obstet Gynecol 98 (2001) 966-968
72. Boorjian S., Choi B.B., Loo M.H., Kim P., and Sandhu J. A rare case of painless gross hematuria. Primary localized AA-type amyloidosis of the urinary bladder. Urology 59 (2002) 137
73. Cheong-Leen R. Primary localised conjunctival amyloidosis presenting as subconjunctival haemorrhage. Eye 15 (2001) 679-680
74. Landa G., Aloni E., Milshtein A., Marcovich A., Mozes M., and Pollack A. Eyelid bleeding and atypical amyloidosis. Am J Ophthalmol 138 (2004) 495-496
75. Lee H.M., Naor J., DeAngelis D., and Rootman D.S. Primary localized conjunctival amyloidosis presenting with recurrence of subconjunctival hemorrhage. Am J Ophthalmol 129 (2000) 245-247
76. Pepys M.B., Herbert J., Hutchinson W.L., et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417 (2002) 254-259
77. McCarron M.O., and Nicoll J.A. Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage. Lancet Neurol 3 (2004) 484-492
78. Yood R.A., Skinner M., Rubinow A., Talarico L., and Cohen A.S. Bleeding manifestations in 100 patients with amyloidosis. JAMA 249 (1983) 1322-1324
79. Leblanc R., Carpenter S., Stewart J., and Pokrupa R. Subacute enlarging cerebral hematoma from amyloid angiopathy. Case report. Neurosurgery 36 (1995) 403-406
80. Chang S.S., Lu C.L., Tsay S.H., Chang F.Y., and Lee S.D. Amyloidosis-induced gastrointestinal bleeding in a patient with multiple myeloma. J Clin Gastroenterol 32 (2001) 161-163
81. Serra L., Poppi M.C., Criscuolo M., and Zandomeneghi R. Primary systemic amyloidosis with giant hepatomegaly and portal hypertension. A case report and a review of the literature. Ital J Gastroenterol 25 (1993) 435-438
82. Harrison R.F., Hawkins P.N., Roche W.R., MacMahon R.F., Hubscher S.G., and Buckels J.A. 'Fragile' liver and massive hepatic haemorrhage due to hereditary amyloidosis. Gut 38 (1996) 151-152
83. Khan A.Z., Escofet X., Roberts K.M., and Salman A.R. Spontaneous splenic rupture-A rare complication of amyloidosis. Swiss Surg 9 (2003) 92-94
84. Mukhopadhya A., Raghuram L., Justus A., Joseph A.J., Eapen C.E., and Chandy G.M. Transcatheter hepatic artery embolization for spontaneous rupture of amyloid liver. Indian J Gastroenterol 23 (2004) 26-27
85. Thaler W., Schatzer G., Eder P., and Fichtel G. Amyloidosis-An unusual case of recurrent intestinal bleeding and sigmoid perforation. Case report with review of the literature. Int J Colorectal Dis 14 (1999) 297-299
86. Greipp P.R., Kyle R.A., and Bowie E.J. Factor X deficiency in primary amyloidosis. Resolution after splenectomy. N Engl J Med 301 (1979) 1050-1051
87. Rosenstein E.D., Itzkowitz S.H., Penziner A.S., Cohen J.I., and Mornaghi R.A. Resolution of factor X deficiency in primary amyloidosis following splenectomy. Arch Intern Med 143 (1983) 597-599
88. Le Quellec A., Sotto A., and Cíurana A.J. Spontaneous resolution of acquired factor X deficiency in amyloidosis. J Intern Med 234 (1993) 329-330
89. Breems D.A., Sonneveld P., de Man R.A., and Leebeek F.W. Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion. Eur J Haematol 72 (2004) 181-185
90. Camoriano J.K., Greipp P.R., Bayer G.K., and Bowie E.J. Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy. N Engl J Med 316 (1987) 1133-1135
91. Kyle R.A., Gertz M.A., Greipp P.R., et al. A trial of three regimens for primary amyloidosis. Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicines. N Engl J Med 336 (1997) 1202-1207
92. Gertz M.A., Lacy M.Q., and Dispenzieri A. Therapy for immunoglobulin light chain amyloidosis. The new and the old. Blood Rev 18 (2004) 17-37
93. Saba N., Sutton D., Ross H., et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 24 (1999) 853-855
94. Zeiher M., Perz J., Linke R.P., et al. No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement. Nephrol Dial Transplant 18 (2003) 2644-2647
95. Aringer M. Periodic fever syndromes-A clinical overview. Acta Med Austriaca 31 (2004) 8-12